Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | GPR3 | P46089 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 2/20 | 0.40 |
| ▸ | PDE2A | O00408 | 1/20 | 0.40 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7359993 | 0.93 | EPHX2 (0.44) | MAPTEPHX2GPR3L3MBTL1KDM4E | |
| SCHEMBL7676729 | 0.93 | KIF11 (0.49) | MAPTEPHX2KIF11NISCHNOTUM | |
| SCHEMBL254957 | 0.86 | MAPT (0.56) | MAPTEPHX2GPR3L3MBTL1KDM4E | |
| Benzenethiol SCHEMBL29279994 | 0.83 | KIF11 (0.41) | MAPTEPHX2GPR3KIF11KMT2A | |
| SCHEMBL2093058 | 0.80 | TRPV4 (0.32) | MAPTEPHX2 | |
| SCHEMBL13610372 | 0.80 | BCHE (0.43) | MAPTEPHX2KIF11ALDH1A1TSHR | |
| SCHEMBL28918414 | 0.79 | MAPT (0.47) | MAPTEPHX2GPR3L3MBTL1KDM4E | |
| SCHEMBL15120976 | 0.79 | MAPT (0.47) | MAPTEPHX2GPR3L3MBTL1KDM4E | |
| SCHEMBL294409 | 0.79 | MAPT (0.47) | MAPTEPHX2GPR3L3MBTL1KDM4E | |
| SCHEMBL19478975 | 0.79 | MAPT (0.47) | MAPTEPHX2GPR3L3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 355 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021127642-A1 | SELECTIVE VALORIZATION OF BIOMASS SUGARS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2021-06-24 | — | — | WO | claimed |
| US-20260109699-A1 | AZOLE DERIVATIVES AS SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2026-04-23 | — | — | US | disclosed |
| US-20250275952-A1 | 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS | MYOKARDIA INC (US) | 2025-09-04 | — | — | US | disclosed |
| EP-4594324-A1 | AZOLE DERIVATIVES AS SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2025-08-06 | — | — | EP | disclosed |
| WO-2025133217-A1 | COMPOUNDS | FLINDR THERAPEUTICS B. V. (NL) | 2025-06-26 | — | — | WO | disclosed |
| CN-120129683-A | Azole derivatives as SHP2 inhibitors | IRBM股份公司 | 2025-06-10 | — | — | CN | disclosed |
| EP-4543859-A1 | 3-(SULPHONYL OR SULFONIMIDOYL)PROP-2-EN-1-YL]-2-OXO-1,2-DIHYDROPYRIDINE-3-CARBOXAMIDE DERIVATIVES | Flindr Therapeutics B.V. (NL) | 2025-04-30 | — | — | EP | disclosed |
| CN-114671864-B | Heteroaryl substituted pyridines and methods of use | 艾伯维公司 | 2025-04-08 | — | — | CN | disclosed |
| CN-119403787-A | 3- (Sulfonyl or iminosulfonyl) prop-2-en-1-yl ] -2-oxo-1, 2-dihydropyridine-3-carboxamide derivatives | 福临德治疗公司 | 2025-02-07 | — | — | CN | disclosed |
| CN-118164961-A | 4-Methylsulfonyl substituted piperidine urea compounds for the treatment of Dilated Cardiomyopathy (DCM) | 迈奥卡迪亚公司 | 2024-06-11 | — | — | CN | disclosed |
| US-5840716-A | ANTIVIRAL AGENTS | MITSUBISHI CHEMICAL CORPORATION (JP) | 1998-11-24 | — | — | US | disclosed |
| EP-0810864-A4 | 2,6-DIARYL PYRIDAZINONES WITH IMMUNOSUPPRESSANT ACTIVITY | MERCK & CO INC (US) | 1998-03-04 | — | — | EP | disclosed |
| WO-1998006706-A1 | SUBSTITUTED P-TRIFLUOROMETHYLPHENYLURACILS | BAYER AKTIENGESELLSCHAFT (DE) | 1998-02-19 | — | — | WO | disclosed |
| WO-1998005635-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES HAVING MMP AND TNF INHIBITORY ACTIVITY | DARWIN DISCOVERY LIMITED (GB) | 1998-02-12 | — | — | WO | disclosed |
| WO-1998004528-A2 | SUBSTITUTED PYRIDINES AND BIPHENYLS AS ANTI-HYPERCHOLESTERINEMIC, ANTI-HYPERLIPOPROTEINEMIC AND ANTI-HYPERGLYCEMIC AGENTS | BAYER CORPORATION (US) | 1998-02-05 | — | — | WO | disclosed |
| EP-0810864-A1 | 2,6-DIARYL PYRIDAZINONES WITH IMMUNOSUPPRESSANT ACTIVITY | Merck & Co., Inc. (US) | 1997-12-10 | — | — | EP | disclosed |
| US-5670504-A | 2,6-diaryl pyridazinones with immunosuppressant activity | MERCK & CO. INC. (US) | 1997-09-23 | — | — | US | disclosed |
| WO-1997028128-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PHARMACEUTICAL AGENTS | ZENECA LIMITED (GB) | 1997-08-07 | — | — | WO | disclosed |
| EP-0785208-A1 | Phosphonate nucleotide compounds | MITSUBISHI CHEMICAL CORPORATION (JP) | 1997-07-23 | — | — | EP | disclosed |
| WO-1996025936-A1 | 2,6-DIARYL PYRIDAZINONES WITH IMMUNOSUPPRESSANT ACTIVITY | MERCK & CO., INC. (US) | 1996-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109699-A1 | AZOLE DERIVATIVES AS SHP2 INHIBITORS | PTPN1, PTPN5, PTPN3 | MAPT 4778/4885EPHX2 1978/4885GPR3 787/4885 |
| US-20250275952-A1 | 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS | TNNI3, UMPS, TNNT2 | MAPT 1759/4885EPHX2 4273/4885GPR3 3353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.